Navigation Links
Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/3/2009

AURORA, Ontario, Sept. 3 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that John Docherty, president and chief operating officer, will present at the Rodman and Renshaw 11th Annual Healthcare Conference at 12:05 p.m. EDT on Wednesday, Sept. 9, at the New York Palace Hotel in New York. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on September 9th, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF".

For further information contact:

    Investor & Media Relations
    Robert Flamm, Ph.D.                        Ian Stone
    Russo Partners LLC                         Russo Partners LLC
    Tel: (212) 845-4226                        Tel: (619) 814-3510
    Email: robert.flamm@russopartnersllc.com   Fax: (619) 955-5318
    www.russopartnersllc.com                   Email:
                                               ian.stone@russopartnersllc.com

This News Release contains certain forward-looking statements regarding the Company's planned presentation at the Rodman & Renshaw 11th Annual Healthcare Conference and the Company's research and development initiatives, which statements can be identified by the use of forward looking terminology such as "will", "developing", "September 9", or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, the fact that the Rodman & Renshaw presentation and the posting of the slide show portion of the presentation on the Company's website are subject to change or cancellation without notice; Helix's need for additional future capital, which may not be available in a timely manner or at all; uncertainty whether L-DOS47 or Topical Interferon Alpha-2b will be successfully developed as a drug or otherwise commercialized; the need for additional research and development, the outcome of which is uncertain; the need for clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; the need for regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; manufacturing and upscaling risks; Helix's dependence on numerous third parties, whose performance and interdependence can critically affect the Company's performance; the effect of competition; and the risk of changes in business strategy or development plans. Such risks and uncertainties, and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information, are more fully described in the Company's latest Annual Information Form, MD&A and other reports filed with the Canadian Securities Regulatory Authorities from time to time at www.sedar.com, and in the Company's Form 20-F and other reports filed with the U.S. S.E.C. from time to time (see www.sec.gov/edgar.shtml). Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations change, except as required by law.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
2. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
3. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
4. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
7. Helix BioPharma Announces Q2 2009 Financial Results
8. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
9. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
10. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
11. Helix BioPharma Announces Q1 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 21, 2017 , ... The Conference Forum has announced the launch of the ... May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO Summit is ... learning, benchmarking and support. , “The Chief Medical Officer faces a unique set of ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Society for Immunotherapy ... as outlined in the Administration’s recently published fiscal year 2018 budget request. , ... of Health (NIH) by $5.8 billion or roughly 20% of its total budget. If ...
(Date:3/22/2017)... , March 22, 2017  Personal Genome ... its cancer testing contract with the U.S. Department ... tumor profiling assay with the company,s new CancerSELECT ... comprehensive, clinically actionable pan-cancer profiling test that includes ... assess potential patient response to checkpoint inhibitor immunotherapies. ...
(Date:3/20/2017)... ... March 20, 2017 , ... SSCI and Whitehouse Laboratories, divisions of Albany ... ! Sponsored by the Parenteral Drug Association (PDA), the New York Interphex Show ... professionals in attendance and more than 625 exhibitors, the educational and networking opportunities are ...
Breaking Biology Technology:
(Date:3/1/2017)... March 1, 2017  Aware, Inc. (NASDAQ: AWRE), a ... Richard P. Moberg has resigned, effective March ... Chief Financial Officer and Treasurer of Aware citing a ... as a member of the Board of Directors of ... co-Chief Executive Officer and co-President, General Counsel has been ...
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
Breaking Biology News(10 mins):